TEGISON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tegison, and when can generic versions of Tegison launch?
Tegison is a drug marketed by Roche and is included in one NDA.
The generic ingredient in TEGISON is etretinate. Additional details are available on the etretinate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TEGISON?
- What are the global sales for TEGISON?
- What is Average Wholesale Price for TEGISON?
Summary for TEGISON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Patent Applications: | 3,318 |
| DailyMed Link: | TEGISON at DailyMed |
US Patents and Regulatory Information for TEGISON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-001 | Sep 30, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-002 | Sep 30, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEGISON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-002 | Sep 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-001 | Sep 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-002 | Sep 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | TEGISON | etretinate | CAPSULE;ORAL | 019369-001 | Sep 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEGISON
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
